Alexander Brown, MD
Rheumatology · Lexington, KYNPI 1043250343
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,881 of the $9,655 with a category attached, or 81.6%. It is spread thinly across 32 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,684 and has fallen 83.6% since, to $605 in 2025.
Across 463 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB Biosciences Inc.$2K
- Amgen$2K
- AbbVie$1K
- Novartis$946
- Pfizer$611
- Johnson & Johnson$514
- plus $2K from 26 others
Across 46 payments — averaging $13,138 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$270K
- Amgen$231K
- UCB SA$46K
- Novartis$33K
- UCB, Inc.$24K
What the payments were for
- Travel & lodging$1,76618%
- Food & beverage$7,88182%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB Biosciences Inc. | 9 | $2,051 |
| Amgen(2 entities) | 106 | $1,827 |
| AbbVie | 72 | $1,333 |
| Novartis | 61 | $946 |
| Pfizer | 54 | $611 |
| Johnson & Johnson | 32 | $514 |
| UCB, Inc. | 24 | $429 |
| Boehringer Ingelheim | 13 | $243 |
| GSK | 13 | $219 |
| E.r. Squibb & Sons, L.L.C. | 10 | $174 |
| Mallinckrodt Hospital Products Inc. | 5 | $165 |
| AstraZeneca(2 entities) | 8 | $148 |
| Regeneron Healthcare Solutions, Inc. | 9 | $136 |
| Lilly USA, LLC | 6 | $120 |
| Bristol Myers Squibb | 5 | $99 |
| Radius Health, Inc. | 5 | $76 |
| Genentech USA, Inc. | 5 | $74 |
| Aurinia Pharma U.S., Inc. | 4 | $67 |
| Sobi, Inc | 3 | $60 |
| Organon | 4 | $54 |
| Daiichi Sankyo Inc. | 2 | $35 |
| EMD Serono, Inc. | 2 | $35 |
| Fresenius Kabi USA, LLC | 2 | $34 |
| Skeletal Dynamics Inc | 1 | $33 |
| Sanofi | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Antares Pharma, Inc. | 1 | $25 |
| Octapharma USA, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Mylan Institutional Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Si-bone, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Humira$114
How this compares
$9,655 in reported general payments places this provider in the 75th percentile of 81 rheumatology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 221 | $1,675,885 |
| Humira(Cf) PenAdalimumab | 139 | $1,087,532 |
| Humira PenAdalimumab | 48 | $546,173 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 52 | $426,210 |
| Xeljanz XrTofacitinib Citrate | 62 | $389,674 |
| OtezlaApremilast | 73 | $367,407 |
| RinvoqUpadacitinib | 41 | $262,538 |
| Cosentyx Sensoready PenSecukinumab | 26 | $244,681 |
| Orencia ClickjectAbatacept | 41 | $227,887 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $189,988 |
| Taltz AutoinjectorIxekizumab | 27 | $179,397 |
| Cimzia (2 Pack)Certolizumab Pegol | 23 | $127,641 |
| OrenciaAbatacept | 21 | $123,530 |
| BenlystaBelimumab | 22 | $98,732 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $98,466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Enbrel, Prolia, Avsola | $1,827 | $538,920139 claims |
| AbbVieRinvoq, Savella | $1,333 | $273,33254 claims |
| E.r. Squibb & Sons, L.L.C.Orencia, Orencia | $174 | $178,54733 claims |
| UCB, Inc.Cimzia (2 Pack) | $429 | $127,64123 claims |
| GSKBenlysta | $219 | $98,73222 claims |
| SanofiKevzara | $29 | $87,63821 claims |
| Lilly USA, LLCOlumiant | $120 | $28,29812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 81 rheumatology providers in Kentucky.
Other rheumatology in Lexington
- Kelly ColeLexington$9K
- Paramarajan PiranavanLexington$8K
- Elaine AlexanderLexington$8K
- Lucia HardiLexington$7K
- Izabela AnticLexington$5K
- Corey HatfieldLexington$4K
- Syed Haider AbbasLexington$3K
- Jeffrey NealLexington$3K
- Amna BatoolLexington$2K
- Robert LightfootLexington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.